Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
22
10
2021
accepted:
06
07
2023
medline:
26
9
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Recent studies suggest that BRAF
Identifiants
pubmed: 37525015
doi: 10.1038/s43018-023-00610-2
pii: 10.1038/s43018-023-00610-2
pmc: PMC10518254
doi:
Substances chimiques
Interleukin-17
0
CTLA-4 Antigen
0
Programmed Cell Death 1 Receptor
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1292-1308Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127–137 (2022).
pubmed: 34818112
doi: 10.1200/JCO.21.02229
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Zimmer, L. et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 400, 1117–1129 (2020).
Iwakura, Y., Ishigame, H., Saijo, S. & Nakae, S. Functional specialization of interleukin-17 family members. Immunity 34, 149–162 (2011).
pubmed: 21349428
doi: 10.1016/j.immuni.2011.02.012
Yao, Z. et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155, 5483–5486 (1995).
Mills, K. H. G. IL-17 and IL-17-producing cells in protection versus pathology. Nat. Rev. Immunol. 23, 38–54 (2023).
pubmed: 35790881
doi: 10.1038/s41577-022-00746-9
Miossec, P. & Kolls, J. K. Targeting IL-17 and T
Vajaitu, C. et al. The central role of inflammation associated with checkpoint inhibitor treatments. J. Immunol. Res. 2018, 4625472 (2018).
Brase, J. C. et al. Role of tumor-infiltrating B cells in clinical outcome of patients with melanoma treated with dabrafenib plus trametinib. Clin. Cancer Res. 27, 4500–4510 (2021).
pubmed: 34108180
pmcid: 9401540
doi: 10.1158/1078-0432.CCR-20-3586
Noubade, R. et al. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 118, 3290–3300 (2011).
pubmed: 21791428
pmcid: 3179398
doi: 10.1182/blood-2011-02-336552
Martel-Pelletier, J., Mineau, F., Jovanovic, D., Di Battista, J. A. & Pelletier, J. P. Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase. Arthritis Rheum. 42, 2399–2409 (2001).
Schubert, M. et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 9, 20 (2018).
pubmed: 29295995
pmcid: 5750219
doi: 10.1038/s41467-017-02391-6
Long, G. V. et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun. 5, 5694 (2014).
pubmed: 25452114
doi: 10.1038/ncomms6694
Rizos, H. et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20, 1965–1977 (2014).
pubmed: 24463458
doi: 10.1158/1078-0432.CCR-13-3122
Kakavand, H. et al. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clin. Cancer Res. 23, 6054–6061 (2017).
pubmed: 28724663
doi: 10.1158/1078-0432.CCR-16-1688
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
pubmed: 26359337
pmcid: 5054517
doi: 10.1126/science.aad0095
Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916–1927 (2019).
pubmed: 31792460
pmcid: 6898788
doi: 10.1038/s41591-019-0654-5
Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell 35, 238–255 (2019).
pubmed: 30753825
doi: 10.1016/j.ccell.2019.01.003
Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017).
pubmed: 29033130
pmcid: 5685550
doi: 10.1016/j.cell.2017.09.028
Helfrich, I., Ullrich, N., Zigrino, P. & Schadendorf, D. Primary tumor versus metastasis: new experimental models for studies on cancer cell homing and metastasis in melanoma. Pigment Cell Melanoma Res. 27, 309–316 (2014).
pubmed: 24314235
doi: 10.1111/pcmr.12204
Wang, J. et al. UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. Pigment Cell Melanoma Res. 30, 428–435 (2017).
pubmed: 28379630
pmcid: 5820096
doi: 10.1111/pcmr.12591
Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 27, 1250–1261 (2021).
pubmed: 34239134
doi: 10.1038/s41591-021-01398-3
Kaptein, P. et al. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Sci. Transl. Med. 14, eabj9779 (2022).
pubmed: 35476594
doi: 10.1126/scitranslmed.abj9779
Grasso, C. S. et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell 38, 500–515 (2020).
pubmed: 32916126
pmcid: 7872287
doi: 10.1016/j.ccell.2020.08.005
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505
pmcid: 4246418
doi: 10.1038/nature13954
Hoch, T. et al. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Sci. Immunol. 7, eabk1692 (2022).
pubmed: 35363540
doi: 10.1126/sciimmunol.abk1692
Daley, J. M., Thomay, A. A., Connolly, M. D., Reichner, J. S. & Albina, J. E. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83, 64–70 (2008).
pubmed: 17884993
doi: 10.1189/jlb.0407247
Camp, R. L., Dolled-Filhart, M. & Rimm, D. L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10, 7252–7259 (2004).
pubmed: 15534099
doi: 10.1158/1078-0432.CCR-04-0713
Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135–2147 (2005).
pubmed: 16291983
doi: 10.1056/NEJMoa050092
Khan, D. & Ahmed, S. A. Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs. Front. Genet. 6, 236 (2015).
pubmed: 26236331
pmcid: 4500956
doi: 10.3389/fgene.2015.00236
Ullah, R., Yin, Q., Snell, A. H. & Wan, L. RAF–MEK–ERK pathway in cancer evolution and treatment. Semin. Cancer Biol. 85, 123–154 (2022).
pubmed: 33992782
doi: 10.1016/j.semcancer.2021.05.010
Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202–216 (2016).
pubmed: 26645196
doi: 10.1158/2159-8290.CD-15-0283
Ruiz de Morales, J. M. G. et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun. Rev. 19, 102429 (2020).
pubmed: 31734402
doi: 10.1016/j.autrev.2019.102429
Kuen, D. S., Kim, B. S. & Chung, Y. Il-17-producing cells in tumor immunity: friends or foes? Immune Netw. 20, e6 (2020).
pubmed: 32158594
pmcid: 7049578
doi: 10.4110/in.2020.20.e6
Bernardini, N. et al. IL-17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art. Int. J. Dermatol. 59, 406–411 (2020).
pubmed: 31663126
doi: 10.1111/ijd.14695
Wilke, C. M. et al. T
pubmed: 21304053
pmcid: 3086699
doi: 10.1093/carcin/bgr019
Chen, C. & Gao, F. H. T
pubmed: 30800130
pmcid: 6375889
doi: 10.3389/fimmu.2019.00187
Chen, Y. S. et al. Locally targeting the IL-17/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum. Gene Ther. 30, 273–285 (2019).
pubmed: 30079767
doi: 10.1089/hum.2018.104
Yan, C. et al. IL-17RC is critically required to maintain baseline A20 production to repress JNK isoform-dependent tumor-specific proliferation. Oncotarget 8, 43153–43168 (2017).
pubmed: 28562353
pmcid: 5522135
doi: 10.18632/oncotarget.17820
Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787–798 (2009).
pubmed: 19879162
pmcid: 2787786
doi: 10.1016/j.immuni.2009.09.014
Kryczek, I., Wei, S., Szeliga, W., Vatan, L. & Zou, W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114, 357–359 (2009).
pubmed: 19289853
pmcid: 2714210
doi: 10.1182/blood-2008-09-177360
Li, M. et al. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J. Cancer Res. Clin. Oncol. 145, 2541–2546 (2019).
pubmed: 31367835
pmcid: 6751277
doi: 10.1007/s00432-019-02982-4
Hirschhorn, D. et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 186, 1432–1447 (2023).
pubmed: 37001503
doi: 10.1016/j.cell.2023.03.007
Ascierto, P. A. et al. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. J. Immunother. Cancer 8, e000391 (2020).
pubmed: 32503946
pmcid: 7279645
doi: 10.1136/jitc-2019-000391
Ribas, A. et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12, 873–883 (2007).
pubmed: 17673618
doi: 10.1634/theoncologist.12-7-873
Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).
pubmed: 26380086
pmcid: 4570556
doi: 10.1186/s40425-015-0081-1
Cortellini, A., Buti, S., Agostinelli, V. & Bersanelli, M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin. Oncol. 46, 362–371 (2019).
pubmed: 31727344
doi: 10.1053/j.seminoncol.2019.10.003
Eggermont, A. M. M. et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 6, 519–527 (2020).
pubmed: 31895407
pmcid: 6990933
doi: 10.1001/jamaoncol.2019.5570
Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509–523 (2022).
pubmed: 35537412
pmcid: 9221568
doi: 10.1016/j.ccell.2022.04.004
Guéry, L. & Hugues, S. T
Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013).
Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).
pubmed: 29141660
pmcid: 5688663
doi: 10.1186/s13059-017-1349-1
Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199–W205 (2019).
pubmed: 31114916
pmcid: 6602449
doi: 10.1093/nar/gkz401
Szklarczyk, D. et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638–D646 (2023).
pubmed: 36370105
doi: 10.1093/nar/gkac1000
Chauvistré, H. et al. Persister state-directed transitioning and vulnerability in melanoma. Nat. Commun. 13, 3055 (2022).
pubmed: 35650266
pmcid: 9160289
doi: 10.1038/s41467-022-30641-9
Meeth, K., Wang, J. X., Micevic, G., Damsky, W. & Bosenberg, M. W. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res. 29, 590–597 (2016).
pubmed: 27287723
pmcid: 5331933
doi: 10.1111/pcmr.12498
Schmittgen, T. D. & Livak, K. J. Analysis of relative gene expression data using real-time quantitative PCR and the 2
Michel, L. et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur. Heart J. 43, 316–329 (2022).
pubmed: 34389849
doi: 10.1093/eurheartj/ehab430
Shihan, M. H., Novo, S. G., Le Marchand, S. J., Wang, Y. & Duncan, M. K. A simple method for quantitating confocal fluorescent images. Biochem. Biophys. Rep. 25, 100916 (2021).
pubmed: 33553685
pmcid: 7856428